Welcome to our dedicated page for Xenon Pharmaceut news (Ticker: XENE), a resource for investors and traders seeking the latest updates and insights on Xenon Pharmaceut stock.
Xenon Pharmaceuticals Inc. (Nasdaq: XENE) is a neuroscience-focused biopharmaceutical company whose news flow centers on clinical progress, scientific data, and corporate developments in neurology and psychiatry. The company is advancing azetukalner, a novel, potent, selective Kv7 potassium channel opener in Phase 3 clinical trials for epilepsy, major depressive disorder (MDD), and bipolar depression (BPD), alongside early-stage Kv7 and NaV1.7 programs in pain and a NaV1.1 program in Dravet syndrome.
News related to XENE often covers clinical milestones, such as enrollment updates and anticipated topline data from Phase 3 studies like X-TOLE2 and X-TOLE3 in focal onset seizures (FOS), X-ACKT in primary generalized tonic-clonic seizures (PGTCS), and the X-NOVA and X-CEED programs in MDD and BPD. Xenon also issues press releases on long-term X-TOLE open-label extension (OLE) data, which include multi-year seizure frequency reductions and analyses of seizure freedom patterns with extended azetukalner treatment.
Investors and clinicians following XENE can expect scientific conference coverage from meetings such as the American Epilepsy Society Annual Meeting, where Xenon presents posters on epilepsy outcomes, depression burden in epilepsy, and pre-clinical data from its NaV1.1 Dravet syndrome program. Additional news items include corporate updates like quarterly financial results, investor conference presentations, investor webinars, and executive appointments, such as the appointment of a Chief Financial Officer in connection with anticipated commercialization activities.
Bookmark this page to monitor Xenon’s latest announcements on its Phase 3 epilepsy and mood disorder programs, early-stage pain pipeline, partnered work with Neurocrine Biosciences, and ongoing regulatory and investor communications.
Xenon Pharmaceuticals (Nasdaq:XENE) reported its 2021 financial results, highlighting significant advancements in clinical trials, particularly for XEN1101, a treatment for epilepsy and major depressive disorder. The Phase 2b X-TOLE trial showed strong efficacy, prompting plans for a Phase 3 development in 2022. Financially, total revenue dropped to $18.4 million with a net loss of $78.9 million, attributed to increased R&D and administrative expenses. Xenon maintains a robust cash position of $551.8 million, sufficient to fund operations into at least 2024.
Xenon Pharmaceuticals Inc. (Nasdaq:XENE) will release its financial results for the year ended December 31, 2021, on March 1, 2022. This announcement follows the closing of U.S. financial markets. A conference call and live audio webcast will take place on the same day at 4:30 PM Eastern Time to discuss these results and provide a corporate update. The company focuses on developing therapies for neurological disorders, particularly epilepsy. Investors can access more details on their website for further updates and replay options.
Xenon Pharmaceuticals Inc. (Nasdaq:XENE) announced its participation in the 11th Annual SVB Leerink Global Healthcare Conference on February 17, 2022. The company will conduct one-on-one investor meetings and a virtual fireside chat.
The chat is scheduled for 5:00-5:30 pm ET and will be presented by Ian Mortimer, the President and CEO. Attendees can access details and webcasts on the company’s website after the event.
Xenon is focused on developing innovative treatments for neurological disorders, particularly epilepsy.
Xenon Pharmaceuticals (Nasdaq:XENE) announced a significant regulatory milestone in its collaboration with Neurocrine Biosciences (Nasdaq:NBIX), resulting in a $15 million aggregate payment to Xenon. The FDA has accepted a protocol amendment that permits inclusion of pediatric patients aged 2-11 in the Phase 2 study of NBI-921352 for SCN8A developmental and epileptic encephalopathy. The payment consists of $6.75 million in cash and an $8.25 million equity investment at a premium price of $31.855 per share. This collaboration aims to enhance epilepsy treatment options for young patients.
Xenon Pharmaceuticals (Nasdaq:XENE) announced its key milestones for 2022, focusing on its lead product, XEN1101, which showed strong efficacy in a Phase 2b clinical trial for focal epilepsy. Plans include an FDA meeting in Q2 2022 and initiating a Phase 3 program later in the year. The company also aims to explore XEN1101 for major depressive disorder. Ongoing pediatric trials for XEN496 are expected to complete in early 2023. Collaborations with Neurocrine Biosciences and Pacira BioSciences are also highlighted, with potential milestone payments pending.
Xenon Pharmaceuticals (Nasdaq:XENE) announced promising results from the Phase 2b X-TOLE trial of XEN1101 for focal epilepsy, with statistically significant seizure reduction (p0.001) across all dose groups. The 25 mg and 20 mg doses achieved median reductions of 52.8% and 46.4% in monthly seizures, respectively. The trial also demonstrated efficacy for difficult-to-treat patients. Xenon plans a Phase 3 trial and has long-term studies underway, reflecting strong potential for XEN1101 in market.
Xenon Pharmaceuticals Inc. (Nasdaq:XENE) has announced its participation in the Annual Meeting of the American Epilepsy Society (AES 2021), highlighting significant updates on its neurology programs. CEO Ian Mortimer emphasized the advancement of XEN1101 and XEN496, with presentations scheduled to showcase Phase 2b clinical trial results and pre-clinical data on epilepsy treatments. A conference call is set for December 3, 2021, to discuss these results. The company aims to address unmet medical needs in epilepsy through innovative therapies.
Xenon Pharmaceuticals Inc. (Nasdaq:XENE) announced that CEO Ian Mortimer and CFO Sherry Aulin will speak at three upcoming virtual investor conferences. The Guggenheim 3rd Annual Neuro/Immunology Conference will take place on November 15, 2021, featuring one-on-one meetings. The Stifel 2021 Virtual Healthcare Conference is scheduled for November 17, 2021, including a fireside chat at 1:20 pm ET. Lastly, the Jefferies London Healthcare Conference is set for November 18, 2021, with an on-demand fireside chat starting at 8:00 am GMT. For updates, visit investor.xenon-pharma.com.
Xenon Pharmaceuticals (Nasdaq:XENE) reported promising insights from its Phase 2b X-TOLE clinical trial for XEN1101, showing significant reductions in focal seizure frequency among adult patients. The therapy is designed for easy administration with once-daily dosing. With $249.6 million in cash and equivalents as of September 30, 2021, and anticipated cash flow until at least 2024, the company is set for the initiation of its Phase 3 trial in adult focal epilepsy in late 2022. Total revenue for Q3 2021 reached $8.1 million, up from $6.6 million a year earlier.
Xenon Pharmaceuticals (Nasdaq:XENE) will report its third quarter 2021 financial results on November 10, 2021, after U.S. market close. A live conference call and webcast will take place at 4:30 pm ET to discuss these results and provide a corporate update. Investors can access the webcast through the company's website. As a clinical-stage biopharmaceutical company, Xenon focuses on developing therapies for neurological disorders, particularly epilepsy, addressing significant unmet medical needs.